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NanomedicinePathology of the brain is caused by the deﬁciency in tissue homeostasis. As the main homeostatic element of the
mammalian nervous system is represented by astrocytes, these glial cells are involved in many, if not all, brain
disorders. Diseased astrocytes undergo a variety of morphological and functional changes, including deregula-
tion of calcium dynamics. To rectify undesirable changes in astrocytes and/or neurones that occur in disease,
we postulate the future use of nanotechnology-based therapeutics. Carbon nanotubes emerged as one of the
most promising advanced nanomaterials for use in neuroprosthesis. Recently, they have been used to affect
morpho-functional characteristics of astrocytes. This article is part of a Special Issue entitled: 12th European
Symposium on Calcium.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Neuroglia was initially described by Rudolf Virchow as a connective
tissue that binds nervous elements together [1] before its cellular nature
was established by Camillo Golgi [2,3]. Astrocytes, a subset of glial cells
that represent the main subject of this review, were named by Michael
von Lenhossek [4]. In the vertebrates, astrocytes are themain homeostat-
ic element of the nervous system. Thus, unsurprisingly, they represent
a substrate of many if not all neurological and psychiatric disorders,
which in general terms all occur as a consequence of homeostasis gone
bad. A prominent component of astrocytic contribution to the brain ho-
meostasis and signalling present itself in variations of intercellular calci-
um levels. This signalling leads to a bidirectional dialogue between
astrocyte and neurones, which is endowed by the intimate structural as-
sociations between these two principal cells of the brain. Of note, these
neural cellular components can undergo morphological and functional
changes in health and disease. In this review, we discuss the aboveopean Symposium on Calcium.
urobiology, 1719 6th Avenue
AL 35294, USA. Tel.: +1 205
of Manchester, Oxford Road,
rights reserved.aspects of the astroglial role in disease. We indicate a possible novel
nanotechnology-based therapeutic approach to treat diseased brain.
Namely, we discuss carbon nanotubes, which emerged as one of the
most promising advanced nanomaterials for use in neuroprosthesis. Al-
though this could be considered as a somewhat premature and provoca-
tive approach, there is palpable evidence that this class of nanomaterials
deserves such an expose.
2. General pathophysiology of neuroglia
The origin of neurological diseases lies in the deﬁcient tissue ho-
meostasis; regardless the aetiology all diseases of the nervous system
can be considered as homeostatic failures. In the vertebrates the main
homeostatic element of the nervous system is represented by neuro-
glia that, in the course of evolution, assume the main role in house-
keeping and stability of the nervous tissue. Neuroglia, by deﬁnition,
cover highly heterogeneous cellular populations that include cells of neu-
ral (astroglia, radial glia, oligodendroglia, NG2 cells, and various types of
peripheral glia, which include for example enteric glia, Schwann cells
and satellite cells) and non-neural (microglia that develops from foetal
macrophages) origins (see [5–10] for comprehensive recent reviews).
Damage to the nervous system, regardless of the aetiology, generally
triggers defensive reactions of the glia, which are broadly represented
by astrogliosis, Wallerian degeneration and activation of microglia
(Fig. 1 and [11]). All these defensive programmes are multi-staged often
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example, represents complex remodelling of astrocyte biochemistry asso-
ciatedwith the release ofmany neurotrophic and neuroprotective factors
that assist neuronal survival and facilitate post-lesioned nervous tissue
remodelling [12]. At the same time severe insults may drive reactive
glia into a neurotoxic state inwhich they releasemultiple deleterious fac-
tors that exacerbate damage of the nervous tissue. All in all, neuroglial
cells represent an important pathogenetic factor, are critical for the pro-
gression of virtually all neurological disorders and instrumental in deﬁn-
ing the outcome of a neuropathological process [11,13–16].
3. Astroglial calcium signalling in neurological diseases
It is universally accepted that intracellular calcium signalling pro-
vides a substrate for astroglial excitability [17–19]. Indeed multiple
receptors expressed by astrocytes in vitro and in situ are linked to
generation of transient ﬂuctuations of Ca2+ concentration in the cy-
tosol and in the intracellular organelles. Astroglial calcium signals
originate from both Ca2+ release from intracellular organelles and
plasmalemmal Ca2+ entry, with these two processes being mutually
regulated. Global Ca2+ signals, cytosolic Ca2+ oscillations and
intercellular Ca2+ waves (the latter integrate astroglial syncytia) are
mainly associated with Ca2+ release from the endoplasmic reticulum
(ER) intracellular store. The ER is well developed in astrocytes and
acts as their principal dynamic Ca2+ store. Activation of ER Ca2+ release
in astrocytes is primarily associated with opening of inositol-1,4,5 tris-
phosphate (InsP3)-gated channels or InsP3 receptors (InsP3Rs) localised
in the endomembrane. InsP3 is produced by phospholipase C coupled to
a multitude of astroglial metabotropic receptors located at the
plasmamembrane of which themost abundant are metabotropic gluta-
mate receptors,metabotropic purinoceptors (of both P2Y and adenosine
subtypes) and possibly adrenoceptors [20,21]. These InsP3-dependentFig. 1. General pathophysiology of neuroglia. Lesions to the brain trigger evolutionary cons
degeneration and activation of microglia.Ca2+ signals developed following activation of metabotropic receptors
have been observed in astroglia in vitro, in situ and in vivo (see e.g.
[22–27]).
Plasmalemmal Ca2+ entry pathway in astrocytes has been investigat-
ed in less detail; nonetheless, it plays an important role for fast and local
Ca2+ signals that are critical for fast signalling in astroglial perisynaptic
processes that follow synaptic transmission. Calcium inﬂux into astro-
cytes occurs through several plasmalemmal routes represented by
store-operated pathways, ionotropic receptors and sodium–calcium ex-
changers. The store-operated entry, activated following depletion of the
ER store in astrocytes, occurs through TRPC1 containing channels which
have substantial Ca2+ permeability [28]. Similarly, Ca2+ can be carried
into astrocytes through ionotropic glutamate receptors mainly of the
N-methyl D-aspartate (NMDA) type differentially expressed by astro-
cytes in different brain regions and through purinergic P2X receptors
[29–31]. Calciumpermeability (PCa/Pmonovalent) of astroglial NMDArecep-
tors has been determined at about 3, while that of P2X receptors varies
between2 for P2X1/5 receptors and>10 for P2X7 receptors [32,33]. Final-
ly Ca2+ can enter astrocytes through a sodium–calciumexchanger (NCX)
operating in the reverse mode. Due to the relatively high cytosolic Na+
concentration in astrocytes, the reversal potential of NCX lies close to a
resting membrane potential [34], and hence even small depolarisations
ofmoderate increases in intracellular Na+ concentration switch astroglial
NCX into the reverse mode [35].
Various neuropathological conditions are associated with aberrant
astroglial Ca2+ signalling and failures of astroglial Ca2+ homeostasis.
For example, in stroke, increased glial Ca2+ signals and pathological
glial Ca2+ waves are likely responsible for spreading the cell death
through the infarction penumbra. These intercellular Ca2+ waves
can trigger a distant release of glutamate and/or ATP from astroglia
that may assume excitotoxic proportions [36]. Pathological astroglial
Ca2+ signalling may also increase following oedema and cell swellingerved neuroglial defensive programmes represented by reactive astrogliosis, Wallerian
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vide a conduit for massive ATP/glutamate release further exacerbat-
ing cell damage [14].
Astroglial calcium signalling is likely to be of pathogenetic rele-
vance for epilepsy. In human brain and in various animal models, ep-
ilepsy is generally associated with prominent reactive astrogliosis,
which also coincides with an impaired ability of astrocytes to buffer
extracellular K+ and to take up extracellular glutamate, both alter-
ations increasing excitability of neuronal networks being thus in-
volved in the pathological cycle [37–40]. Epilepsy has also been
implicated in remodelling astroglial Ca2+ signalling [41]. Epileptic as-
trocytes, for example, can experience larger Ca2+ load through Ca2+
entry via α-amino-3-hydroxy-5-methyl-isoxazole propionate (AMPA)
glutamate receptors. Astrocytes isolated from tissue samples obtained
from patients suffering from temporal lobe epilepsy express a rather
speciﬁc type of AMPA receptors. These receptors contain the ﬂip variant
of the GluA1 subunit that substantially prolongs glutamate-induced
channel opening and thus increases Ca2+ entry [42]. Similarly, in auto-
immune child epilepsy and Rasmussen's encephalitis astrocytes display
spontaneous Ca2+ oscillations which probably result from a modiﬁca-
tion in the GluA3 subunit of AMPA receptors [43]. There are also specu-
lations that aberrant astroglial Ca2+ signallingmay induce synchronous
release of glutamate from astrocytes that may, at least in certain condi-
tions, initiate seizures [44]. Astroglial Ca2+ regulation is also impaired
in various neurodegenerative diseases. Exposure of cultured astrocytes
to β-amyloid (the full length peptide 1–42 or the neurotoxic 25–35
fragment) triggered Ca2+ oscillations which were associated with
Ca2+-dependent glutathione depletion in both astrocytes and neurons,
and neuronal death [45]. The aberrant Ca2+ oscillations and spontane-
ously occurring long-range intercellular Ca2+waveswere also detected
in astrocytes in the in vivo imaging of the brain of a transgenic model of
Alzheimer's disease (AD) [46].
4. Astrodegeneration and astroglial atrophy in neurological diseases
Formany years only the hypertrophic reaction of astrocytes that sig-
nals astrogliosis has been considered relevant for pathophysiology. In
recent years, however, numerous examples of degeneration of astro-
cytes that causes either speciﬁc astroglial death or astroglial atrophy
have been found in various neuropathologies. Furthermore in many
cases functional dystrophy of astroglial cells was the key element in
homoeostatic failure that caused neuronal death and lay at the very
core of neuropathology.
Functional failure of astrocytes, for example, is a key pathogenetic
factor in various forms of toxic damage to the nervous tissue. Toxic
encephalopathies that resulted from poisoning with heavy metals,
such as methylmercury intoxication (or Minamata disease), acute
and chronic intoxication with lead, manganese and aluminium all in-
clude astrocytes as a primary pathogenic factor. Astroglial cells specif-
ically accumulate these heavy metals which generally results in the
down-regulation of plasmalemmal glutamate transporter expression,
failure in astrocytic glutamate uptake with subsequent excitotoxicity,
neuronal death and rapidly developing neurodegeneration [16]. Sim-
ilarly, functional deﬁcits in astroglial glutamate uptake lie at the core
of another rapidly progressing neurodegeneration represented by
Wernicke encephalopathy; in human astrocytes isolated from the dis-
eased tissues the level of plasmalemmal glutamate transporter ex-
pression was reduced by 60–70% with obvious grave consequences
for glutamate clearance [47,48].
Hypotrophic astrocytes were also detected in several types of psy-
chiatric disorders. In schizophrenia the signiﬁcant atrophic changes
were found in astrocytes as well is in oligodendroglia [49–51].
Astrodegeneration in schizophrenia may underlie generalised alter-
ations of glutamatergic transmission and in particular NMDA receptor
mediated signalling bearing in mind that astrocytes are an important
source of D-serine involved in physiological modulation of NMDAreceptors [52,53]. Similarly astroglial atrophy, reduction in astrocyte
density and deﬁcits in glial ﬁbrillary acidic protein (GFAP) expression
were found in bi-polar disorders andmajor depression in both human
tissues [54,55] and in animal models of depression [56]. It is tempting
to suggest that reduced astroglial coverage and synaptic support can
play a role in disrupted synaptic connectivity, a prominent character-
istic of these diseases.
Atrophic changes in astrocytes were also identiﬁed in several
types of neurodegenerative disorders [57–59]. Most importantly
these degenerative changes in astroglia are found in the early stages
of neurodegeneration before the appearance of neuronal-associated
clinical symptoms.
In amyotrophic lateral sclerosis (ALS) the very ﬁrst pathological
changes appear in astroglia, which become atrophic and even die by
apoptosis. The atrophic astrocytes in ALS become vulnerable to gluta-
mate excitotoxicity, their glutamate uptake become compromised
and they release neurotoxic factors [58,60,61]. In animal models of
ALS that express mutant forms of superoxide dismutase SOD1 (that
is associated with a familial form of ALS) speciﬁc silencing of the
gene in astrocytes delays the development of pathology, further cor-
roborating the pathological relevance of astroglia [62,63].
Early astroglial atrophy was also found in animal models of AD.
This astroglial atrophy (measured by a decrease in GFAP proﬁles)
had a speciﬁc spatio-temporal development that is somewhat similar
to that of histopathological features of the AD in humans. Astroglial
atrophy in triple transgenic AD model developed very early
(~1 months of age) in the entorhinal cortex, later (~6 months of
age) it appeared in the prefrontal cortex and even later (~9 months
of age) in the hippocampus [64–66]. This pattern almost precisely
mimicked the development of β-amyloid load in humans that begins
in the entorhinal cortex and spreads through the prefrontal cortical
areas to the hippocampus [67]. Morphological atrophy of astrocytes
was also paralleled with functional deﬁcits, which once more where
region speciﬁc. In the entorhinal cortex astrocytes failed to display
any signs for reactive astrogliosis even after the appearance of extra-
cellular β-amyloid deposits [66]. In the prefrontal cortex astrocytes
demonstrated similar reluctance to become reactive and moreover
from early ages (1–6 months) a signiﬁcant down-regulation of
astroglial glutamine synthetase was observed [64]. These deﬁcits in
glutamine synthetase may indicate alterations in an operational ca-
pacity of glutamine–glutamate shuttle with obvious implications for
glutamatergic and γ-amino butyric acid (GABA)ergic synaptic trans-
mission. In the hippocampus, the appearance of senile plaques trig-
gered an astrogliotic response. Reactive astrocytes were attracted to
the plagues and perivascular β-amyloid deposits; this astrogliotic re-
action, however, was not associated with the disruption of astroglial
domain organisation [65].
Atrophic astrocytes in AD may have fundamental pathogenetic
importance. A decrease in astroglial synaptic coverage and impaired
glutamate homeostasis may signal early alterations in synaptic con-
nectivity which are generally regarded as ﬁrst pathological changes
in AD [68]. Astroglial atrophy may also signal deﬁcient metabolic sup-
port, the feature also generally associated with developing AD pathol-
ogy [67].
Atrophic astrocyteswere also found in other types of dementia includ-
ing fronto-temporal dementia, Pick's disease, fronto-temporal lobar de-
generation, thalamic dementia, and HIV-associated dementia [69–71].
Functional astroglial dystrophy due to speciﬁc expression of loss of func-
tion mutated genes encoding NPC-1 or NPC-2 proteins expressed in
astroglial perisynaptic processes and involved in synaptogenesis is con-
sidered to be a primary cause of the Niemann–Pick disease type C, a
neurodegenerationwithhepatosplenomegaly [72]. Finally functional dys-
trophy of astrocytes is detected in Huntington disease, which compro-
mises astroglial glutamate uptake and production of ascorbic acid [73].
Having outlined morpho-functional changes in astrocytes in dis-
eased brain, we turn our attention to carbon nanotubes that have
Fig. 2. Transmission electron microscopy (TEM) micrograph of carbon nanotubes
displaying diameters in the range of 50 nm.
Modiﬁed from Fig. 7 of [74].
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logical and functional changes in neural cells. Such actions could
translate into therapeutic interventions for some neural disorders.
5. Carbon nanotubes as ion channel modulators
Here we brieﬂy review the discovery, characteristics, and the ac-
tions of carbon nanotubes (CNTs) on ion channels in an attempt to
raise awareness of this novel material as a potential future modulator
of astrocytic intracellular calcium dynamics even though such a CNT
action has not been described in these glial cells yet.
In 1955 Radushkevich and Lukyanovich show the ﬁrst evidence of
nano-sized carbon tubes [74] (Fig. 2). However, the present interest
in CNTs spurs from the efforts of two groups in early 1990s ([75,76],
reviewed in [77]).
CNTs are composed of rolled up sheets of graphene forming either a
single cylinder, i.e. a single-walled carbon nanotube (SWCNT), or concen-
tric cylinders, and in the latter case the resulting CNTs are arbitrarily des-
ignated either as a double-walled CNT containing two concentric
cylinders or multi-walled carbon nanotubes (MWCNTs) containing mul-
tiple concentric cylinders (Fig. 3). The size of CNTs typically ranges from
0.4 to 2 nm in diameter for SWCNTs and 2 to 100 nm for MWCNTs
while their length can vary from one to several hundred micrometres
(reviewed in [78,79]).
Following their synthesis that requires ametal catalyst, CNTs are often
puriﬁed (which leads to the removal of themetal catalyst) and thenmod-
iﬁed to improve their biocompatibility or enable them to perform new
functions by attaching various compounds to them (for a comprehensive
review on CNTs see [78,80]). One functionalization approach is to make
CNTs water-soluble, i.e. colloid solutes [81], a highly desired trait when
attempting to apply them to living cells [81–83]. The use of (un)modiﬁed
CNTs, however, led to the discovery that CNTs could represent a newclass
of ion channel modulators. Such evidence has been gathered for potassi-
um [84] and calcium [81] ion channels.
Unmodiﬁed CNTs were used on Chinese hamster ovary (CHO) cells
expressing a variety of potassium ion channels. The CNTs' effects on the
potassium ion channels were determined by whole cell current record-
ings. Although SWCNTs affected all the types of potassium ion channels
that were expressed in CHO cells, human ether-a-go-go-related gene
channels showed the greatest sensitivity to CNTs as seen by the reduc-
tion in recorded currents. Interestingly, the small diameter CNTs
(0.9 nm), i.e. SWCNTs, had the greatest channel blocking ability, which
was reversible and concentration-dependent.MWCNTs,whichwere larg-
er, didnot block channel activity. The authors postulated that the SWCNTs
obstructed the channel pore and interrupted transition of the channel be-
tween the open and inactive states.
In a follow-up study, SWCNTs were functionalized to change their
channel blocking ability [85]. Here, SWCNTs were modiﬁed with
carboxyl groups (SWCNT-COOH) and were also covalently conjugated
with the sulfhydryl probe 2-aminoethylmethane thiosulfonate (MTSET)
that binds to cysteine residues. Whole cell current recordings of CHO
cells expressing hyperpolarization-activated cyclic nucleotide-gated cat-
ion channels (HCN) were obtained. These currents were reversibly
blocked when CHO cells were exposed to SWCNT-COOH. However,
when SWCNT-MTSET were applied the block became irreversible,
which was ascribed to the interaction of MTSET and cysteines on the
HCN. These results indicate that it may be possible to gain speciﬁcity of
the SWCNT channel blocking ability by functionalizing CNTs.
The ﬁnding that CNTs can affect intracellular Ca2+ homeostasis
came as a consequence of two morphological studies using cultured
hippocampal neurons [81,86]. The initial study provided the evidence
for applicability of CNTs as a carrier of a biomolecule to affect neuro-
nal growth [87]. By using ﬁxed materials of hippocampal neurons
from primary cultures and scanning electron microscopy, the authors
demonstrated that neurons formed one or two neuronal neurites,
when grown on the surfaces of unmodiﬁed MWCNTs; this growth wasmuch reduced than that of neurons grown on thewell known permissive
scaffold polyethyleneimine. To address whether functionalization of
MWCNTs with biological molecules can be used to control the number
of neurites, their outgrowth and branching, Mattson et al. coated
MWCNTs with 4-hydroxynonenal (4-HNE) by physical adsorption. The
rationale for the usage of this lipid peroxidation product came from its ef-
fect on intracellular Ca2+ levels in cultured hippocampal neurones [88].
Since Ca2+ inﬂux can regulate neurite elongation [89], it is likely that
4-HNE would also exhibit such action. Indeed, neurons grown on
MWCNTs coated with 4-HNE exhibited increased neurite number, length
and branchingwhen compared to neurons grown on bareMWCNTs. This
effect appeared to bemediated by 4-HNE, since increased growthwas not
evident when neurons were grown on MWCNTs which adsorption of
4-HNE was carried out in an excess of histidine that binds to 4-HNE
[90]. Thus, non-covalent modiﬁcations of CNTs with biomolecules can
be used to modulate neurite outgrowth and neurite branching.
Ni et al. [81] treated hippocampal neurons grown in cell culturewith
water-soluble SWCNTs, functionalized with either polyethylene glycol
(PEG) or poly-m-aminobenzene sulphonic acid (PABS), to demonstrate
that either formof soluble SWCNTs caused a reduced number of neurites
and growth cones, while incidentally those neurites were elongated.
Observed effects were concentration-dependent. Since previous work
had shown that cytoplasmic Ca2+ elevations, via voltage-dependent
Ca2+ channels (VDCCs), could affect neurite length and motility
[86,89,91], Ni et al. [81] investigated whether the altered outgrowth
caused bywater-soluble SWCNTs could be the result of modulation of in-
tracellular Ca2+ homeostasis. They monitored the cytoplasmic Ca2+ re-
sponses in neurons using the Ca2+ indicator ﬂuo-3. The intracellular
Ca2+ elevation was evoked by exposure to high (50 mM) extracellular
K+, which caused cell depolarization and entry of Ca2+ through VDCC
(Fig. 4a); the depolarization-dependent Ca2+ entry was sensitive to the
VDCC blocker Cd2+. Neurons incubated with SWCNT-PEG showed a sig-
niﬁcant dose-dependent impairment in cytoplasmic Ca2+ elevation
whichmay be due to CNTs interferingwith the functioning of Ca2+ chan-
nels (Fig. 4b).
An increase in neuronal intracellular Ca2+ levels can regulate plas-
ma membrane/vesicular recycling, which has been implicated to play
a role in the rate of neurite elongation [92]. Consequently, Malarkey at
al. examined whether SWCNT-PEG could affect membrane recycling
[93] using the ﬂuorescent dye N-(3-triethylammoniumpropyl)-4-
(4-(dibutylamino)styrl)pyridinium dibromide (FM 1–43), which is
plasmamembrane-impermeable and is taken up by cells through endo-
cytosis. SWCNT-PEG inhibited a depolarization-dependent load of the
dye [93]. Subsequent experiments indicated that this inhibitory action
Fig. 3. TEMmicrographs of carbon nanotubes. a) MWCNTs [98] and (b) SWCNTs [75]. (c) TEMmicrograph showing bundles of SWCNTs. The dark spots are catalyst particles used for
the nanotube growth. (d, e) Schematics of (d) MWVNT and (e) SWCNT.
The TEM micrographs shown in (a) and (b) were kindly provided by Sumio Iijima, NEC, Japan and reproduced with the permission of the Nature Publishing Group. Adopted from
[78].
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Hence, the exocytotic incorporation of vesicles into the plasma mem-
brane was not balanced by the endocytotic retrieval in the presence of
SWCNTs, which could effectively cause the increase in neurite length
observed by Ni et al. [81]. It should be noted that CNTs were appropri-
ately puriﬁed in both of these studies [81,93]. In the absence of appro-
priate puriﬁcation, however, the CNTs blocking effects on Ca2+
channels could be masked or even mistaken for the action by a metal
catalyst, if it can become available in biologically relevant cationic
form [94].
As we already disclosed above, it is presently unknown whether
CNTs can affect Ca2+ homeostasis in astrocytes. Based on the above ex-
citing ﬁndings, it appears warranted to study this issue in the near fu-
ture, especially that these novel materials may prove to be useful in
correcting aberrant Ca2+ signalling seen in astrocytes in various patho-
physiological conditions. It is tempting to speculate, however, that CNTs
would affect plasmalemmal Ca2+ (and K+) channels in astrocytes. Be-
cause astrocytes do not readily express a high density of VDCC, it is like-
ly that CNTs would mainly affect store-operated Ca2+ entry [28].
6. Carbon nanotubes affect morpho-functional characteristics of
astrocytes
As previouslymentioned, CNTs have emerged as a promisingmaterial
for use in neural prosthesis [95];water-soluble SWCNTs promoted select-
ed neurite outgrowth of cultured neurones [81] and in vivo at the site of
an acute spinal cord injury [96]. Additionally, SWCNTs can modulate the
morpho-functional characteristics of astrocytes [83]. When added to the
culturingmedium, SWCNT-PEG and SWCNT-PABSwere able to make as-
trocytes larger and stellate/mature along with the increase in GFAP im-
munoreactivity (GFAP-ir). Morphology of live mouse cortical astrocytes
was based on their accumulation of the vital dye calcein and quantitativeassessment of the area, perimeter and form factor of the cells [97]; the lat-
ter metrics is a measure of the roundness of an object/cell. Astrocytes
treatedwith SWCNTs showed elongated astrocytic somata and increased
extension of processes, changes consistent with morphological matura-
tion, whichwas evidenced as a signiﬁcant increase in the area and perim-
eter values alongwith a signiﬁcant decrease in the form factor. In addition
to this morphological plasticity, astrocytes treated with SWCNTs showed
a change in their functionality based on the quantitative assessment of
GFAP-ir, i.e. its density, content and occupancy (see details in [83]). All
three quantitative GFAP-ir parametersmeasured showed a signiﬁcant in-
creasewhen astrocytes were treatedwith SWCNTs. It is then tempting to
speculate that SWCNTs could be used to affect the course of, for example,
Alzheimer's disease (AD). Asmentioned earlier, a recent study on a triple
transgenic mouse (3xTg) model of a hereditary form of AD showed that
astrocytes in the entorhinal cortex of 3xTg-AD mice undergo atrophy in
the very early ages (1 month) of the animal, sustained up to 12 months,
resulting in astroglial domain shrinkage and reduction of astrocytic
arborisation [64–66]. Consequently, a plausible therapeutic strategy to
slow down the progression of the AD could be to use SWCNTs on the
brain during the early onset of AD.7. Concluding remarks
The intent of this review was to discuss the role of astroglia calci-
um signalling and their morpho-functional changes in the brain pa-
thology. As these cells are the main homeostatic element of the
nervous system, they are likely affected in or represent a main sub-
strate for neurological and psychiatric disorders. Since in many in-
stances we lack efﬁcient treatments for neural disorders, we put
forward a provocative notion that nanomaterials could be used as
novel therapeutics. Although we presented the initial case for CNTs,
Fig. 4. SWCNT-PEG reduces depolarization-induced intracellular Ca2+ accumulation in
neurons. Cellswere treatedwith SWCNT-PEG for 3 days in culture and throughout the en-
tire course of the experiment. a) Time lapse of ﬂuo-3 ﬂuorescence, reporting on Ca2+
levels in neurons. Depolarization of neurons evoked by high extracellular K+ (HiK+;
solid bar), caused an increase of their intracellular Ca2+ levels (control; black squares).
SWCNT-PEG reduced the HiK+-induced intracellular Ca2+ accumulationwhen compared
to untreated neurons. b) This effect of SWCNT-PEG is dose-dependent; peak values of
HiK+-induced intracellular Ca2+ accumulation in neurons. Points and bars represent
means±standard errors of means; concentrations (c) of SWCNT-PEG are given in μg/
mL; asterisks indicate a signiﬁcant difference inmeasurementwhen compared to control.
Adopted from [81].
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should be kept on the horizon for nanomedicine.
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